OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
Dirk Schadendorf, Jason J. Luke, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e007501-e007501
Open Access | Times Cited: 6
Dirk Schadendorf, Jason J. Luke, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e007501-e007501
Open Access | Times Cited: 6
Showing 6 citing articles:
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (2024) Vol. 215, pp. 115153-115153
Open Access | Times Cited: 11
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (2024) Vol. 215, pp. 115153-115153
Open Access | Times Cited: 11
The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma
Catherine Zhou, Antien L. Mooyaart, Thamila Kerkour, et al.
European Journal of Epidemiology (2025)
Open Access | Times Cited: 1
Catherine Zhou, Antien L. Mooyaart, Thamila Kerkour, et al.
European Journal of Epidemiology (2025)
Open Access | Times Cited: 1
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H. Yoon, Merrick I. Ross, Brian Gastman, et al.
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2756-2764
Closed Access
Charles H. Yoon, Merrick I. Ross, Brian Gastman, et al.
Annals of Surgical Oncology (2025) Vol. 32, Iss. 4, pp. 2756-2764
Closed Access
Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients
Shigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Shigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer
Mengjie Zhang, Jian Wu, Yongxin Zhang, et al.
Annals of Surgical Oncology (2024)
Closed Access | Times Cited: 1
Mengjie Zhang, Jian Wu, Yongxin Zhang, et al.
Annals of Surgical Oncology (2024)
Closed Access | Times Cited: 1
Advances in predictive biomarkers for melanoma immunotherapy
Wenjie Ma, Wanlin Liu, Jingqin Zhong, et al.
Holistic Integrative Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 1
Wenjie Ma, Wanlin Liu, Jingqin Zhong, et al.
Holistic Integrative Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 1
